CRISPR Delivery Systems
Read more about the webinar - CRISPR Delivery Systems
What you will learn from this webinar
- The challenges associated with trafficking CRISPR components into cells for therapeutic applications
- How novel delivery systems presented by our speakers address these challenges
- Possibilities for tissue- and organ-specific delivery of CRISPR components
- How various delivery systems are likely to contribute to future CRISPR therapies
Trafficking CRISPR components into cells remains a major challenge in the genome editing field. There are currently three key categories of CRISPR delivery methods – viral, chemical, and physical – each of which comprises several different vehicles. Viral delivery vehicles include adeno-associated viruses (AAVs), full-size adenoviruses (AdVs), and lentiviruses (LVs). Chemical delivery vehicles, otherwise known as nano delivery vehicles, include liposomes and lipid nanoparticles, lipoplexes and polyplexes, inorganic nanoparticles, and cell-penetrating peptides. Physical delivery vehicles include electroporation, microinjection, microfluidics, and hydrodynamic delivery.
The vehicle chosen for delivery must be compatible with several other key factors to achieve efficient and safe CRISPR editing, especially for therapeutic applications. These factors include the CRISPR cargo used, whether it be a DNA plasmid, mRNA, or a ribonucleoprotein complex, the nature of the experiment i.e. in vivo, ex vivo, or in vitro, and the target cell or organism. There has been significant recent progress in CRISPR delivery research, with improvements in older delivery vehicles and the emergence of novel delivery technologies.
On-demand Access here.